Universität zu Köln

Park, Julie R., Villablanca, Judith G., Hero, Barbara, Kushner, Brian H., Wheatley, Keith, Beiske, Klaus H., Ladenstein, Ruth L., Baruchel, Sylvain, Macy, Margaret E., Moreno, Lucas, Seibel, Nita L., Pearson, Andrew D., Matthay, Katherine K. and Valteau-Couanet, Dominique (2022). Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer, 128 (21). S. 3775 - 3784. HOBOKEN: WILEY. ISSN 1097-0142

Full text not available from this repository.

Abstract

Background International standardized criteria for eligibility, evaluable disease sites, and disease response assessment in patients with refractory, progressive, or relapsed high-risk neuroblastoma enrolled in early-phase clinical trials are lacking. Methods A National Cancer Institute-sponsored Clinical Trials Planning Meeting was convened to develop an international consensus to refine the tumor site eligibility criteria and evaluation of disease response for early-phase clinical trials in children with high-risk neuroblastoma. Results Standardized data collection of patient and disease characteristics (including specified genomic data), eligibility criteria, a definition of evaluable disease, and response evaluations for primary and metastatic sites of disease were developed. Eligibility included two distinct patient groups: progressive disease and refractory disease. The refractory disease group was subdivided into responding persistent disease and stable persistent disease to better capture the clinical heterogeneity of refractory neuroblastoma. Requirements for defining disease evaluable for a response assessment were provided; they included requirements for biopsy to confirm viable neuroblastoma and/or ganglioneuroblastoma in those patients with soft tissue or bone disease not avid for iodine-123 meta-iodobenzylguanidine. Standardized evaluations for response components and time intervals for response evaluations were established. Conclusions The use of international consensus eligibility, evaluability, and response criteria for early-phase clinical studies will facilitate the collection of comparable data across international trials and promote more rapid identification of effective treatment regimens for high-risk neuroblastoma.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Park, Julie R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Villablanca, Judith G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hero, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Kushner, Brian H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wheatley, Keith UNSPECIFIED UNSPECIFIED UNSPECIFIED Beiske, Klaus H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ladenstein, Ruth L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Baruchel, Sylvain UNSPECIFIED UNSPECIFIED UNSPECIFIED Macy, Margaret E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Moreno, Lucas UNSPECIFIED UNSPECIFIED UNSPECIFIED Seibel, Nita L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pearson, Andrew D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Matthay, Katherine K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Valteau-Couanet, Dominique UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-696434
DOI:	10.1002/cncr.34445
Journal or Publication Title:	Cancer
Volume:	128
Number:	21
Page Range:	S. 3775 - 3784
Date:	2022
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1097-0142
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language HIGH-RISK NEUROBLASTOMA; STAGE 4 NEUROBLASTOMA; COLONY-STIMULATING FACTOR; MONOCLONAL-ANTIBODY 3F8; METAIODOBENZYLGUANIDINE SCINTIGRAPHY; IRINOTECAN-TEMOZOLOMIDE; MARROW DISEASE; BONE-MARROW; I TRIAL; CHILDREN Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/69643